Monoclonal Antibodies for Eosinophilic Esophagitis and Gastritis

Monoclonal antibodies, particularly dupilumab, demonstrate efficacy in reducing peak eosinophil count and improving EREFS in EoE, with a favorable safety profile. Although the systematic review of EoG studies suggests similar trends, the limited number of RCTs precludes conducting a meta-analysis. Small sample sizes, lack of patient-reported outcomes, and high heterogeneity highlight the need for larger, standardized trials to confirm these findings and to assess long-term effects.